311 related articles for article (PubMed ID: 21523499)
21. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Cascinu S; Gasparini G; Catalano V; Silva RR; Pancera G; Morabito A; Giordani P; Gattuso D; Catalano G
Ann Oncol; 1999 Nov; 10(11):1377-9. PubMed ID: 10631469
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.
Sahora K; Schindl M; Kuehrer I; Eisenhut A; Werba G; Brostjan C; Telek B; Ba'ssalamah A; Stift J; Schoppmann SF; Gnant M
Anticancer Res; 2014 May; 34(5):2377-84. PubMed ID: 24778046
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Allendorf JD; Lauerman M; Bill A; DiGiorgi M; Goetz N; Vakiani E; Remotti H; Schrope B; Sherman W; Hall M; Fine RL; Chabot JA
J Gastrointest Surg; 2008 Jan; 12(1):91-100. PubMed ID: 17786524
[TBL] [Abstract][Full Text] [Related]
24. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Kulke MH; Tempero MA; Niedzwiecki D; Hollis DR; Kindler HL; Cusnir M; Enzinger PC; Gorsch SM; Goldberg RM; Mayer RJ
J Clin Oncol; 2009 Nov; 27(33):5506-12. PubMed ID: 19858396
[TBL] [Abstract][Full Text] [Related]
25. Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Masui T; Doi R; Kawaguchi Y; Sato A; Nakano K; Ito T; Anazawa T; Takaori K; Uemoto S
Surg Today; 2016 Nov; 46(11):1282-9. PubMed ID: 26860274
[TBL] [Abstract][Full Text] [Related]
26. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
31. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
[TBL] [Abstract][Full Text] [Related]
32. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Bickenbach KA; Gonen M; Tang LH; O'Reilly E; Goodman K; Brennan MF; D'Angelica MI; Dematteo RP; Fong Y; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2012 May; 19(5):1663-9. PubMed ID: 22130621
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP
Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant
Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
[TBL] [Abstract][Full Text] [Related]
36. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Cunningham SC; Cusnir M; Burdick RK; Van Echo DA; Moesinger R
Clin Adv Hematol Oncol; 2003 Dec; 1(12):741-2; discussion 743. PubMed ID: 16258479
[No Abstract] [Full Text] [Related]
38. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
39. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
[TBL] [Abstract][Full Text] [Related]
40. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
